A cotton rat model of experimental human respiratory syncytial virus (RSV) and human parainfluenza virus type 3 (PIV-3) infection was used to examine the efficacy of FRHNp, a novel chimeric glycoprotein which contains the extraceUular regions of the fusion glycoprotein of RSV and the attachment glycoprotein of PIV-3, as a single subunit vaccine against these two viruses. This work was prompted by previous cotton rat studies that demonstrated that the major protective antigens of the two viruses were these glycoproteins. FRHN P was expressed in insect cells using a recombinant baculovirus. Vaccination with FgHN F resulted in induction of both RSV and PIV-3 neutralizing antibody and doses of 200 ng completely protected rats from either RSV or PIV-3 challenge. These results demonstrate that in the cotton rat animal model a single chimeric glycoprotein can be an effective vaccine against both RSV and PIV-3.
Human respiratory syncytial virus (RSV) and human parainfluenza virus type 3 (PIV-3) are the two leading causes of virus-induced bronchiolitis and pneumonia in the U.S.A. (Chanock & McIntosh, 1990; McIntosh & Chanock, 1990) . RSV alone results in the hospitalization of approximately 91000 children in the U.S.A. (Neilman, 1990) and in a cyclical increase in infant mortality during the winter epidemics (Anderson et al., 1990) . PIV-3 infections occur throughout the year and along with RSV is a major cause of lower respiratory tract disease in infants and young children (Tyeryar, 1983) . Vaccines are not currently available for either of these viruses.
RSV and PIV-3 are both members of the Paramyxoviridae family. Although these viruses are serologically distinct, their glycoproteins are structurally similar. Both viruses code for a fusion (F) glycoprotein which is proteolytically cleaved from its F 0 precursor into disulphide-bonded F1 and F 2 subunits. The F glycoproteins are class I glycoproteins with signal regions at their amino termini and anchor regions at their carboxyl termini (Gruber & Levine, 1983; Spriggs et al., 1986) . The viruses have class II attachment glycoproteins with signal/anchor regions at their amino termini resulting in the protrusion of the glycoproteins' carboxyl termini from the cell membrane (Levine et al., 1987; Elango et al., 1986) . The attachment glycoprotein for PIV-3 has haemagglutinin and neuraminidase activities and is termed HN (Scheid et al., 1972) . The RSV attachment protein (G) does not possess either of these activities (Levine et al., 1987) .
Animal studies have demonstrated that the fusion and attachment glycoproteins of RSV and PIV-3 (individually or in combination) can protect against challenge with their respective virus (Brideau et al., 1989 (Brideau et al., , 1993 Olmsted et al., 1986 Olmsted et al., , 1988 Spriggs et al., 1987) . A subunit vaccine for RSV, FG, and a subunit vaccine for PIV-3, FHN, have been developed by our group (Brideau et aI., 1989 (Brideau et aI., , 1993 Lehman et al., 1993; Wathen et al., 1989) . These vaccines are soluble chimeric glycoproteins expressed using eukaryotic expression vector systems and are composed of the extracellular regions of the RSV F and G glycoproteins (FG) or the extracellular regions of the PIV-3 F and HN glycoproteins (FHN). Interestingly, these and other studies (Merz et al., 1980; Johnson et al., 1987; Spriggs et al., 1987; van Wyke Coelingh et al., 1987; Ray et al., 1988 Ray et al., , 1989 Olmsted et al., 1988; Hall et al., 1991) have demonstrated that the majority of neutralizing antibody induced by these recombinant vaccines is against the F glycoprotein in the case of RSV and the HN glycoprotein in the case of PIV-3. In this study we combined the RSV F and PIV-3 HN glycoproteins into a single glycoprotein, F~HNp, in order to evaluate the effects of combining two dominant immunogens into a single protein vaccine capable of Plasmids pFBBL-5, pUC-HN, pUC-HN3B and pAC373-FHN have been previously described (Wathen et al., 1989 b; Lehman et al., 1993) . Relevant restriction endonuclease sites are shown; restriction sites lost during the cloning steps are shown with an X through them. Clone pAC373-F~HN~ was co-transfected with wild-type baculovirus DNA into Sf9 cells and recombinant baculoviruses expressing the FRHN P glycoprotein were isolated. (b) Regions of the 978 amino acid F~HNp protein that were derived from the RSV F and PIV-3 HN proteins are shown along with the four-amino acid junction region generated by the BamHI/BglII linkers used in the construction of the protecting cotton rats against both RSV and PIV-3 infection. The scheme used to construct a secreted form of the chimeric FRHN r glycoprotein and the insertion of this gene into the baculovirus transfer vector pAC373 (Summers & Smith, 1987) is outlined in Fig. 1 (a) . The chimeric FRHN P protein consists of amino acids 1 to 488 of the RSV F gene and amino acids 87 to 572 of the PIV-3 HN gene with the addition of four extra amino acids at the junction (Fig. 1 b) . Following co-transfection of Sf9 cells with the pAC373-FRHN P clone and wild-type Autographa californica nuclear polyhedrosis virus DNA, a recombinant baculovirus expressing the F•HNp glycoprotein was isolated as described previously (Lehman et al., 1993) . Expression of the FRHN P glycoprotein in baculovirus-infected Sf9 cells was determined following immunoprecipitation using either RSV F-, RSV G-, PIV-3 F-or PIV-3 HN-specific monoclonal antibodies (MAbs) (Fig. 2) . Baculovirus-infected cells were labelled from 24 to 48 h post-infection (p.i.) with [35S]methionine. Proteins in the medium were immunoprecipitated and examined by gel electrophoresis. As expected, only the RSV F-and PIV-3 HN-specific MAbs immunoprecipitated the FaHNp protein (Fig. 2a) . Under nonreducing conditions the FRHN P protein appears as a single protein with an M r of approximately 120K (lane 2, Fig. 2b ). Under reducing conditions the 120K protein remained the predominant form but two additional minor protein bands with Mrs of approximately 105K and 100K were also detected (Fig. 2a, b) . The 105K protein is the product of proteolytic cleavage of the RSV F portion of the chimeric protein at the F1-F2 cleavage site (Gruber & Levine, 1983) . Under reducing conditions the disulphide-linked 15K F2 subunit is released from the FRHN P protein but is not visible under the electrophoretic conditions used. The presence of the 100K protein band suggested that a second proteolytic site existed within the RSV F portion of the FRHN P protein. Previously we demonstrated that when the RSV F glycoprotein was expressed in insect cells it was only partially cleaved into its F1 and F2 subunits, and that two F1 bands differing in size by 5K were present due to a secondary cleavage site recognized by an insect cell protease (Wathen et al., 1989b) . Therefore, the two smaller F~HNp protein bands seen on the reducing gel can be accounted for by partial cleavage at the two sites located within the F portion of this chimeric glycoprotein.
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chimeric protein. Amino acids 1 to 488 were derived from the RSV F protein, amino acids 493 to 978 were derived from the PIV-3 HN protein (corresponds to amino acids 87 to 572 of the HN protein) whereas amino acids 489 to 492 were added by the BamHI/BglII linkers. . The source of the MAbs has been previously described (Wathen et al., 1989a; Brideau et al., 1993) . The samples were separated on a 10% polyacrylamide gel under reducing conditions (boiled in the presence of 2-mercaptoethanol). (b) Baculovirusexpressed FrtHN P immunoprecipitated with MAbs 112 and 13-5 and separated on a 15% polyacrylamide gel under reducing (lane 1) and non-reducing (lane 2) conditions.' (c) Silver-stained 10% polyacrylamide gel of immunoaffinity-purified baculovirus-expressed Fr~HN e (lane 1). Twenty gg of sample was separated under reducing conditions. Lane M, M r markers. t 50 % end-point titres determined by ELISA as described (Wathen et al., 1989a) .
Purification of the FRHN P protein was done by immunoaffinity chromatography using an HN (13-5) MAb column following the procedure that was used for expression and purification of the PIV-3 FHN protein (Lehman et al., 1993) . The FRHN P protein was eluted from the immunoaffinity column in a low pH buffer and analysed on a silver-stained SDS-polyacrylamide gel (Fig. 2 c) . The F~HNp protein eluted from the column as a 100K protein suggesting that during the purification the protein was completely cleaved at the secondary proteolytic site found in the F portion of the chimeric protein. A second major staining band of M r 200K was also detected which may be an aggregate of the FRHN P protein, although we have not done Western blots to confirm this. The purity of the FRHN P protein (100K band) was determined by densitometry of the silver-stained gel and was estimated to be approximately 50 % of the total protein.
FRHNv was used to immunize cotton rats and sera were reacted with various forms of either the RSV F and G glycoproteins or with the PIV-3 F and HN glycoproteins. Table 1 summarizes the serum IgG antibody responses to various RSV and PIV-3 antigens following two immunizations with the FRHN P protein, as detected using ELISA (Brideau et al., 1989) . The baculovirus expression system was used to produce the FG, FHN, Fr~HNp, PIV-3 F, PIV-3 HN and gp50T (unrelated antigen, truncated version of the pseudorabies virus gp50 glycoprotein) glycoproteins and the RSV F and G proteins were expressed from recombinant vaccinia virus vectors (Olmsted et al., , 1988 . Sera from FRHNp-immunized animals recognized the FG, FHN, PIV-3 HN and RSV F glycoproteins in RSV-and PIV-3-infected cell lysates. The same sera did not react with the PIV-3 F glycoprotein or the RSV G glycoprotein. In addition, the F~HN v glycoprotein was also recognized by immune sera taken from animals immunized with either the FG or FHN glycoproteins (data not shown). The ELISA data demonstrated that sera taken from animals vaccinated with the FgHNp protein specifically recognized the RSV F and PIV-3 HN glycoproteins.
The protective role of the FRHN P glycoprotein was studied in cotton rats and was compared with the response elicited by RSV FG, PIV-3 FHN or PIV-3 HN glycoproteins (Table 2) . Animals were immunized twice (days 1 and 14) intramuscularly with different doses (50 to 800 ng) of these antigens prepared using aluminium hydroxide (Alhydrogel, Superfos) as an adjuvant. At 10 days after the second vaccination sera were prepared and tested for the presence of RSV-and PIV-3-neutralizing antibodies (Brideau et al., 1989) . Two weeks after the second vaccination the animals were challenged intranasally with either RSV or PIV-3 and 4 days later lung tissue was removed and virus titres were determined using HEp-2 cells (Brideau et al., 1989) . Animals immunized with 50 ng (lowest dose tested) doses of FRHNp were found to have both anti-RSV-and anti-PIV-3-specific neutralizing antibodies and a significant (~< 103-fold, P < 0'001) reduction in the level of either virus in lung tissue (Table 2) . A dose of 200 ng was found q Neutralizing antibody titres are the mean of five animals per group. :~ Titres are the mean of infected animals. Limit of detectability was 1.69 (logt0), § P compares each group with two or more infected animals to the appropriate Alhydrogeltreated group, as determined by Student's t-test.
II Animals received 100 lal of RSV or PIV-3 equalling 1 x 106 to 2 x 106 p.f.u, intranasally (day 28).
to protect cotton rat lungs totally against challenge with either R S V or PIV-3. W h e n the relative protective effect of the F n H N P glycoprotein was c o m p a r e d to F G -, F H N -, or H N -i m m u n i z e d animals, it was found that the a m o u n t o f F n H N P (100 to 200 ng) required to protect animals completely against RSV or PIV-3 was comp a r a b l e to that of either F G or F H N and was better than that of thd H N protein (Table 2) . These results clearly d e m o n s t r a t e that the F n H N P protein can serve as a single subunit vaccine against R S V and PIV-3. In summary, the results presented in this study clearly d e m o n s t r a t e that the F n H N r protein is i m m u n o g e n i c in cotton rats and affords protection from b o t h R S V and PIV-3 challenge. This study was based u p o n observations that the vast m a j o r i t y o f the I g G a n t i b o d y response, as measured by E L I S A or after a b s o r p t i o n analysis o f i m m u n e sera following vaccination with the RSV F G and PIV-3 F H N chimeric glycoproteins, was directed against the F p o r t i o n o f the F G and the H N p o r t i o n of the F H N (Brideau et al., 1989 (Brideau et al., , 1993 . These same studies, however, d e m o n s t r a t e d that the chimeric glycoproteins were superior immunogenically to secreted forms of the individual glycoproteins (Brideau et al., 1989 (Brideau et al., , 1993 The present study provides evidence for this hypothesis since the PIV-3 H N linked to the R S V F protein provides greater p r o t e c t i o n against PIV-3 t h a n the H N protein alone. Chimeric proteins offer unique advantages in the development of multimeric vaccines. Because of the similar patient p o p u l a t i o n s and diseases o f these viruses, the development o f a multimeric vaccine against b o t h RSV and PIV-3 is an i m p o r t a n t goal. 
